Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
105.25
-0.21 (-0.20%)
At close: May 31, 2024, 4:00 PM
105.15
-0.10 (-0.10%)
After-hours: May 31, 2024, 6:56 PM EDT
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $3.84B in the twelve months ending March 31, 2024, with 2.81% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $901.98M with 1.03% year-over-year growth. In the year 2023, Jazz Pharmaceuticals had annual revenue of $3.83B with 4.78% growth.
Revenue (ttm)
$3.84B
Revenue Growth
+2.81%
P/S Ratio
1.73
Revenue / Employee
$1,372,634
Employees
2,800
Market Cap
6.63B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
Dec 31, 2005 | 21.44M | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Ensign Group | 3.85B |
Acadia Healthcare Company | 2.99B |
Masimo | 1.98B |
Exelixis | 1.85B |
HealthEquity | 999.59M |
Intra-Cellular Therapies | 513.93M |
Legend Biotech | 342.80M |
Blueprint Medicines | 282.21M |
JAZZ News
- 1 day ago - Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 - PRNewsWire
- 3 days ago - Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 - PRNewsWire
- 4 days ago - Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - PRNewsWire
- 4 days ago - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer - PRNewsWire
- 11 days ago - Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance - PRNewsWire
- 5 weeks ago - Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 - PRNewsWire